AZD6234
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
AstraZeneca · Phase 2 · Active, not recruiting · Enrollment 16
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| AZD6234 (sub-study 1) | n/r | n/r | n/r | n/r |
| Placebo (sub-study 1) | n/r | n/r | n/r | n/r |
| AZD9550(sub-study 2 Cohort A) | n/r | n/r | n/r | n/r |
| Placebo (sub-study 2 Cohort A) | n/r | n/r | n/r | n/r |
| AZD6234 in combination with AZD9550 (sub-study 2 Cohort B) | n/r | n/r | n/r | n/r |
| Placebo (sub-study 2 Cohort B) | n/r | n/r | n/r | n/r |
Not shown
- AZD6234 (sub-study 1): endpoint not reported
- Placebo (sub-study 1): endpoint not reported
- AZD9550(sub-study 2 Cohort A): endpoint not reported
- Placebo (sub-study 2 Cohort A): endpoint not reported
- AZD6234 in combination with AZD9550 (sub-study 2 Cohort B): endpoint not reported
- Placebo (sub-study 2 Cohort B): endpoint not reported